Q-Med AB (publ) applies for delisting, postpones the annual general meeting and convenes an extraordinary general meeting

Galderma's public offer for Q-Med AB (publ) ("Q-Med" or the "Company") was
declared unconditional on 25 February 2011. Galderma controls more than 90 per
cent of the shares in Q-Med and has requested compulsory acquisition in respect
of the shares in Q-Med that Galderma does not own.

As requested by Galderma, the Board of Q-Med has convened an Extraordinary
General Meeting to be held on 28 March 2011, for the purposes of, amongst other
things, appointing a new board.

Further, at the proposal of Galderma the Board of Q-Med has resolved to apply
for delisting of the Company's shares from NASDAQ OMX Stockholm ("NASDAQ OMX").
The last day of trading in the Company's shares on NASDAQ OMX will be announced
as soon as the Company has received confirmation from NASDAQ OMX.

At the proposal of Galderma, the Board of Q-Med has also resolved to postpone
the Annual General Meeting scheduled to be held on 28 April 2011. A new date for
the Annual General Meeting will be set by the new Board of Q-Med after the
Extraordinary General Meeting on 28 March 2011.

Uppsala March 3, 2011
The Board of Q-Med AB (publ)

Queries should be addressed to:
Alexander Kotsinas, CFO
Tel: +46 73 500 111
Carina Bolin, General Counsel
Tel: +46 70 974 9117


The information in this press release is such as that which Q-Med is required to
disclose in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. The information was submitted for disclosure
at 7.40 p.m. on March 3, 2011.


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q-Med has about 650 coworkers, with almost 400 at the company's head
office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid
Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web: www.q-
med.com

[HUG#1494459]